Abiraterone in the treatment of metastatic castration-resistant prostate cancer
EA Mostaghel - Cancer management and research, 2014 - Taylor & Francis
Androgen deprivation therapy remains the single most effective treatment for the initial
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
EA Mostaghel - Cancer Management and Research, 2014 - osti.gov
Androgen deprivation therapy remains the single most effective treatment for the initial
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
EA Mostaghel - Cancer Management and Research, 2014 - dovepress.com
Androgen deprivation therapy remains the single most effective treatment for the initial
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
EA Mostaghel - Cancer Management and Research, 2014 - search.proquest.com
Androgen deprivation therapy remains the single most effective treatment for the initial
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
EA Mostaghel - Cancer Management and Research, 2014 - inis.iaea.org
[en] Androgen deprivation therapy remains the single most effective treatment for the initial
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
EA Mostaghel - Cancer management and research, 2014 - pubmed.ncbi.nlm.nih.gov
Androgen deprivation therapy remains the single most effective treatment for the initial
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
[引用][C] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
E Mostaghel - Cancer Management and Research, 2014 - cir.nii.ac.jp
Abiraterone in the treatment of metastatic castration-resistant prostate cancer | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
EA Mostaghel - Cancer Management and Research, 2014 - go.gale.com
Androgen deprivation therapy remains the single most effective treatment for the initial
therapy of advanced prostate cancer, but is uniformly marked by progression to …
therapy of advanced prostate cancer, but is uniformly marked by progression to …
[HTML][HTML] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
EA Mostaghel - Cancer Management and Research, 2014 - ncbi.nlm.nih.gov
Androgen deprivation therapy remains the single most effective treatment for the initial
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
Abiraterone in the treatment of metastatic castration-resistant prostate cancer.
EA Mostaghel - Cancer Management and Research, 2014 - europepmc.org
Androgen deprivation therapy remains the single most effective treatment for the initial
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …
therapy of advanced prostate cancer, but is uniformly marked by progression to castration …